|

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Peking University People's Hospital1

Indications

  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma1
  • Cancer1

Other1 trial

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.